CLDXCelldex Therapeutics, Inc.

$2B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+1374.6% YoY

Gross Profit

-$9M-255.1% margin

Operating Income

-$13M-386.2% margin

Net Income

-$13M-384.3% margin

EPS (Diluted)

$-0.34

QoQ Revenue Growth

+408.0%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$205M

Total Liabilities

$22M

Stockholders' Equity

$182M

Cash & Equivalents

$43M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$236,000	+1374.6%
Gross Profit	-$9M	-$9M	+6.3%
Operating Income	-$13M	-$11M	-18.3%
Net Income	-$13M	-$11M	-21.2%

Revenue Segments

Grant

$3M99%

Service

$26,0001%

CLDX Q2 2021 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena